The Rise of Osavampator: A New Contender in Adjunctive Depression Treatment
In a crowded market of SSRIs, SNRIs, and antipsychotic adjuncts, Osavampator represents a truly novel direction. Its efficacy is among the strongest seen in recent trials, its safety profile is remarkably clean, and its mechanism of action provides an opportunity to break from the limitations of monoamine-based therapy.




.png)


